← Back to Screener
Check-Cap Ltd. (MBAI)
Price$1.90
Favorite Metrics
Price vs S&P 500 (26W)-6.57%
Price vs S&P 500 (4W)5.84%
Market Capitalization$13.56M
All Metrics
Book Value / Share (Quarterly)$0.64
Price vs S&P 500 (YTD)11.91%
10-Day Avg Trading Volume0.16M
EPS (Annual)$-4.30
ROI (Annual)-74.17%
Cash / Share (Quarterly)$0.24
ROA (Last FY)-6670.82%
Cash Flow / Share (Annual)$-1.37
P/B Ratio3.60x
P/B Ratio (Quarterly)1.20x
Net Income / Employee (Annual)$-0
EPS Incl Extra (Annual)$-4.30
Current Ratio (Annual)0.15x
Quick Ratio (Quarterly)0.71x
3-Month Avg Trading Volume1.74M
52-Week Price Return179.35%
52-Week High$3.92
EPS Excl Extra (Annual)$-4.30
26-Week Price Return2.17%
Quick Ratio (Annual)0.15x
13-Week Price Return8.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.71x
Enterprise Value$12.401
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.05
3-Month Return Std Dev244.88%
ROE (Last FY)-74.17%
EPS Basic Excl Extra (Annual)$-4.30
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)144.25%
Year-to-Date Return16.05%
5-Day Price Return4.44%
EPS Normalized (Annual)$-4.30
Month-to-Date Return16.77%
EBITD / Share (Annual)$-4.41
Price vs S&P 500 (13W)5.18%
Beta0.87x
52-Week Low$0.59
Analyst Recommendations
Apr 2024
May 2024
Jun 2024
Jul 2024
2.17
2.17
2.17
2.17
Industry Peers — X-Ray Equipment(4)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
MBAICheck-Cap Ltd. | — | — | — | — | $1.90 |
GEHCGE HealthCare Technologies Inc. Common Stock | 1.65x | 3.74% | 39.98% | 13.40% | $74.15 |
PHGKONINKLIJKE PHILIPS N.V. | 1.78x | 0.59% | 45.43% | 8.08% | $29.19 |
HOLXHologic Inc | 4.11x | 1.66% | 56.51% | 17.56% | $76.01 |
BFLYButterfly Network, Inc. | 14.22x | — | 46.85% | -88.53% | $5.49 |
About
Check-Cap Ltd is a clinical-stage diagnostics company developing C-Scan, an ingestible capsule that uses low-dose X-rays to screen for colorectal cancer and polyps without patient preparation or data retrieval. The swallowed capsule naturally transits the gastrointestinal tract while imaging, eliminating the need for colonoscopy prep. Based in Israel, the company plans to commercialize the technology in the United States, Europe, and Japan.